Chung Eun Jee, Kim Ji Hyun, Ahn Hyun Seok, Koh Hyoung Jun
The Institute of Vision Research, Department of Ophthalmology,Yonsei University College of Medicine, Seoul, South Korea.
Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1727-30. doi: 10.1007/s00417-007-0661-y. Epub 2007 Aug 10.
This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive zone I retinopathy of prematurity (ROP).
A male patient, born at 25 weeks gestation with a birth weight of 884 g, received indirect laser photocoagulation and a 0.75 mg intravitreal bevacizumab injection to each eye for aggressive stage 3 zone I ROP. Structural outcomes were evaluated 3 months after treatment.
At 3-month follow-up, treatment had resulted in ROP regression, prompt resolution of plus signs and neovascular proliferation in both eyes, and no signs of systemic or ocular adverse events.
The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt regression of aggressive zone I ROP.
本报告描述了联合激光光凝和玻璃体内注射贝伐单抗治疗I区侵袭性早产儿视网膜病变（ROP）的应用。
一名孕25周出生、出生体重884g的男性患者，因I区3期侵袭性ROP接受了双眼间接激光光凝和0.75mg玻璃体内贝伐单抗注射。治疗3个月后评估结构转归。
在3个月的随访中，治疗使ROP消退，双眼加征和新生血管增殖迅速消退，且无全身或眼部不良事件迹象。
间接激光光凝和玻璃体内贝伐单抗注射联合应用耐受性良好，可使I区侵袭性ROP迅速消退。
Zotero 插件